Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05821842 · ClinicalTrials.gov registry record · NA
Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion
A NA study of Nasal Congestion and Inflammations, sponsored by Third Wave Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05821842: Completed NA study of Nasal Congestion and Inflammations, sponsored by Third Wave Therapeutics.
NCT05821842 is a NA study of Nasal Congestion and Inflammations that has completed, run by Third Wave Therapeutics. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05821842, a NA study of Nasal Congestion and Inflammations, has completed, sponsored by Third Wave Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the safety and effectiveness of Sonu for the treatment of patients suffering from moderate to severe nasal congestion.
Primary Outcome
Change in nasal congestion sub-score compared to baseline. The nasal congestion sub-score is reported on a scale of 0-3. 0 is the minimum and 3 is the maximum. Higher scores mean worse outcomes.
Conditions Studied
Interventions
- DEVICE Sonu
Study Locations (1)
California
- San Francisco Otolaryngology Medical Group - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
What the finished NCT05821842 record still lists
NCT05821842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Nasal Congestion and Inflammations appearing as the primary indexed condition, and to 1 intervention - of which Sonu is the first listed.
NCT05821842 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05821842 about?
NCT05821842 is a clinical study titled "Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion". To demonstrate the safety and effectiveness of Sonu for the treatment of patients suffering from moderate to severe nasal congestion.
What is the current status of trial NCT05821842?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2022-03-23. Estimated completion is 2023-06-30.
What conditions does trial NCT05821842 study?
This clinical trial studies the following conditions: Nasal Congestion and Inflammations.
What interventions are being tested in trial NCT05821842?
The interventions under investigation include: Sonu (DEVICE).
Who is sponsoring clinical trial NCT05821842?
This trial is sponsored by Third Wave Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05821842 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasal Congestion and Inflammations
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05821842's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI